+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

IV and Oral Iron Drugs Market - Global Outlook and Forecast 2019-2024

  • ID: 4772998
  • Report
  • Region: Global
  • 241 pages
  • Arizton
1 of 4

FEATURED COMPANIES

  • Akebia Therapeutics
  • AMAG Pharmaceuticals
  • Daiichi Sankyo Company
  • Pfizer
  • Salveo Lifecare
  • Shield Therapeutics
  • MORE
The IV and oral iron drugs market is expected to reach around $7.69 million by 2024, growing at a CAGR of about 11% during 2018–2024.

The IV and oral iron drugs market is expected to be driven by multiple factors such as expanding the pool of target population with iron deficiency, the high demand for non-dextran IV iron therapeutics, the increasing demand for iron drugs among dialysis and non-dialysis patients, and the commercial availability of branded iron therapeutics.

The growing prevalence of iron deficiency is driving vendors, government organizations, and healthcare professionals to increase awareness about iron replacement therapies. This is expected to impact the IV and oral iron drugs market significantly. Several types of research and clinical studies have confirmed that early diagnosis and prompt treatment improves the quality of life and physical condition of IDA patients and alleviates fatigue and cognitive deficits. Further, the expected commericlization of branded IV drugs such as Feraccru, Monofer, and Injectafer in newer markets will contribute to the growth of the global IV and oral iron drugs market.

Currently, the IV and oral iron drugs market is scaling new heights due to the increase in strategic collaborations and licensing opportunities. These strategic partnerships and in-licensing/out-licensing opportunities will allow key players to gain competitive advantage and increase geographical reach. Further, they will also reduce R&D expenses and offer scope for easy market access among geographies. Originator companies are partnering with large and medium-sized, regional and local, and biotechnology companies to increase the penetration of IV and oral iron drugs worldwide. They are also opting for strategic alliances to receive additional funds for the continued commercialization of drugs among geographies.

The research report on the IV and oral iron drugs market covers market sizing and forecast, market share, industry trends, growth drivers, and vendor analysis. The study includes insights on segmentation by Route of Administration (oral and intravenous), applications (nephrology, OBGYN, surgeries, gastroenterology, oncology, and heart failure), and geography (North America, Europe, APAC, and ROW).

The study considers the present scenario of the IV and oral iron drugs market and its market dynamics for the period 2019−2024. The report covers a detailed overview of several market growth enablers, restraints, and trends. It covers both the demand and supply aspect of the market. It profiles and analyzes leading and prominent companies operating in the IV and oral iron drugs market.

IV and Oral Iron Drugs Market: Segmentation

This market research report includes a detailed segmentation of the market by Route of Administration (ROA), application, and geography. The IV and oral iron drugs market by ROA can be segmented into oral iron drugs and intravenous (IV) iron drugs. The oral iron drugs segment captured more than half of the market in 2018. Oral iron drugs are generally used as the first line of treatment to overcome iron deficiency among children, adults, especially pregnant women. The IV iron drugs market is growing at a faster rate due to expected launches of several branded IV iron drugs in the medicine market. One of the major factors for the significant growth for IV iron drugs is the increased uptake of branded IV drugs in the US and European markets. Hence, the rising global medicine and healthcare expenditure and the accurate and convenient access to IV iron dosages are expected to drive IV and oral iron drugs market during the forecast period. The IV and oral iron drugs market by application is segmented into nephrology, OBGYN, surgeries, gastroenterology, oncology, and heart failure. In 2018, the nephrology segment accounted for a share of more than half of the IV and oral iron drugs market.

The availability of approved prescription iron drugs and the increased demand for IV iron drugs, especially in developed economies for treating ID/IDA in CKD patients are further driving market growth. Over the past few years, the IV and oral iron drugs market has witnessed new IV iron formulations such as iron sucrose. It is replacing high molecular weight iron dextran, especially in dialysis patients. The OBGYN segment constituted around one-third share of the IV and oral iron drugs market in 2018. Also, the IV and oral iron drugs market for gastroenterology is growing at a significant rate and is likely to increase at a similar pace during the forecast period due to the increased need for iron drugs among patients with GI diseases such as IBD and celiac disease.

Market Segmentation by ROA
  • Oral Iron Drug
  • IVIron Drugs
Market Segmentation by Application
  • Nephrology
  • OBGYN
  • Surgeries
  • Gastroenterology
  • Oncology
  • Heart failure (HF)
IV and Oral Iron Drugs Market: Geography

The IV and oral iron drugs market by geography can be segmented into North America, Europe, APAC, and ROW. In 2018, North America dominated the market and is expected to grow at a CAGR of around 13% during the forecast period. The strong presence of major vendors and a large proportion of the population with ID, coupled with better treatment access to ID and IDA, especially branded drugs, is the primary factor for high market shares. Europe is the second largest market for IV & oral iron drugs. Germany, the UK, France, Italy, and Spain are the major revenue contributors in the region. High disease awareness, high uptake of branded iron therapeutics, and accelerated healthcare spending are the primary factors responsible for market growth. APAC is the third largest market for iron therapeutics. It is expected to grow at a steady rate in the coming years due to growing awareness about the application of iron drugs for chronic disorders. The IV and oral iron drugs market in ROW is growing at a moderate rate. Most end-users prefer generic and OTC oral iron drugs over branded ones in these regions. Brazil, Egypt, Iran, Israel, Mexico, South Arabia, and South Africa are expected to emerge as major markets for IV and oral iron drugs in ROW.

Market Segmentation by Geography
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • APAC
  • Japan
  • China
  • ROW
  • Brazil
Key Vendor Analysis

The IV and oral iron drugs market is characterized by the presence of a few global and many regional and local players. The vendors are offering branded oral and IV iron drugs, which are generating significant revenues, especially Europe and the US. Therefore, the IV and oral iron drugs market has huge growth potential for branded drugs in these markets. The demand for branded drugs is low in many developing and low-income countries due to the availability of low-cost generic drugs, especially oral iron drugs.

Leading Vendors
  • Daiichi Sankyo Company
  • Vifor Pharma
Other Prominent Vendors
  • Akebia Therapeutics
  • Business Overview
  • Major Product Offerings
  • Allergan
  • AMAG Pharmaceuticals
  • AOP Orphan Pharmaceuticals
  • Pharmacosmos
  • Sanofi
  • Shield Therapeutics
Other Vendors
  • AZAD Pharma
  • Cirondrugs
  • MEDICE
  • Pfizer
  • Salveo Lifecare
  • Sunny Pharmaceutical
Key Market Insights

The analysis of the IV and oral iron drugs market provides market sizing and growth opportunities for the forecast period 2019–2024.
  • Offers market sizing and growth prospects of the IV and oral iron drugs market for the forecast period 2019–2024
  • Provides comprehensive insights on the latest industry trends, market forecast, and growth drivers in the IV and oral iron drugs market
  • Includes a detailed analysis of market growth drivers, challenges, and investment opportunities
  • Delivers a complete overview of market segments and the regional outlook of the IV and oral iron drugs market
  • Offers an exhaustive summary of the vendor landscape, competitive analysis, and key market strategies to gain a competitive advantage in the IV and oral iron drugs market
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Akebia Therapeutics
  • AMAG Pharmaceuticals
  • Daiichi Sankyo Company
  • Pfizer
  • Salveo Lifecare
  • Shield Therapeutics
  • MORE
1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the study
4.4 Market Segments
4.4.1 Market Segmentation by Products
4.4.2 Market Segmentation by Applications
4.4.3 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at A Glance

7 Introduction
7.1 Iron Deficiency: An Overview
7.1.1 Symptoms of ID
7.1.2 Causes of ID
7.1.3 Treatment

8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Expanding Population Pool with Iron Deficiency
8.1.2 High Demand for Non-dextran IV Iron Therapeutics
8.1.3 Rising Demand Among Dialysis and Non-dialysis Patients
8.2 Market Growth Restraints
8.2.1 Adverse Events Associated with Oral & IV Iron Drugs
8.2.2 Presence of Alternative Options for Treating ID and IDA
8.2.3 Availability of Low-cost Generic Iron Drugs
8.3 Market Opportunities & Trends
8.3.1 Investigational Iron Drugs and Expected Approvals in Newer Markets
8.3.2 Increase in Strategic Collaborations and Licensing Opportunities
8.3.3 Availability of Branded Iron Therapeutics and Expanded Indication Approvals

9 Global IV & Oral Iron Drugs Market
9.1 Market Overview
9.2 Market Size & Forecast
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry

10 By Route Of Administration
10.1 Market snapshot & Growth Engine
10.2 Market Overview
10.3 Oral Iron Drugs
10.3.1 Market Overview
10.3.2 Market Size & Forecast
10.4 IV Iron Drugs
10.4.1 Market Overview
10.4.2 Market Size & Forecast

11 By Application
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Nephrology
11.3.1 Market Overview
11.3.2 Market Size & Forecast
11.4 Obstetrics and Gynecology (OBGYN)
11.4.1 Market Overview
11.4.2 Market Size & Forecast
11.5 Surgeries
11.5.1 Market Overview
11.5.2 Market Size & Forecast
11.6 Gastroenterology
11.6.1 Market Overview
11.6.2 Market Size & Forecast
11.7 Oncology
11.7.1 Market Overview
11.7.2 Market Size & Forecast
11.8 Heart failure
11.8.1 Market Overview
11.8.2 Market Size & Forecast

12 By Geography
12.1 Market Snapshot & Growth Engine
12.2 Market Overview

13 North America
13.1 Market Overview
13.2 Market Size & Forecast
13.3 Key Countries
13.3.1 US: Market Size & Forecast
13.3.2 Canada: Market Size & Forecast

14 Europe
14.1 Market Overview
14.2 Market Size & Forecast
14.3 Key Countries
14.3.1 Germany: Market Size & Forecast
14.3.2 UK: Market Size & Forecast
14.3.3 France: Market Size & Forecast
14.3.4 Spain: Market Size & Forecast
14.3.5 Italy: Market Size & Forecast

15 APAC
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 Japan: Market Size & Forecast
15.3.2 China: Market Size & Forecast
15.3.3 Australia: Market Size & Forecast
15.3.4 South Korea: Market Size & Forecast

16 Latin America
16.1 Market Overview
16.1.1 Market Size & Forecast
16.2 Key Countries
16.2.1 Brazil: Market Size & Forecast
16.2.2 Mexico: Market Size & Forecast

17 Middle-East And Africa
17.1 Market Overview
17.1.1 Market Size & Forecast
17.2 Key Countries
17.2.1 Turkey: Market Size & Forecast
17.2.2 Saudi Arabia: Market Size & Forecast

18 Competitive Landscape
18.1 Competition Overview

19 Key Vendors
19.1 Vifor Pharma Group
19.1.1 Business Overview
19.1.2 Vifor Pharma Group in Global IV & Oral Iron Drugs Market
19.1.3 Key Strategies
19.1.4 Key Strengths
19.1.5 Key Opportunities
19.2 Daiichi Sankyo Company
19.2.1 Business Overview
19.2.2 Major Product Offerings
19.2.3 Daiichi Sankyo Company in Global IV & Oral Iron Drugs Market
19.2.4 Key Strategies
19.2.5 Key Strengths
19.2.6 Key Opportunities

20 Prominent Vendors
20.1 AMAG Pharmaceuticals
20.1.1 Business Overview
20.1.2 Major Product Offerings
20.1.3 AMAG Pharmaceuticals in Global IV & Oral Iron Drugs Market
20.1.4 Key Strategies
20.1.5 Key Strengths
20.1.6 Key Opportunities
20.2 Akebia Therapeutics
20.2.1 Business Overview
20.2.2 Major Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 Shield Therapeutics
20.3.1 Business Overview
20.3.2 Major Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Pharmacosmos
20.4.1 Business Overview
20.4.2 Major Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Allergan
20.5.1 Business Overview
20.5.2 Major Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
20.6 Sanofi
20.6.1 Business Overview
20.6.2 Major Product Offerings
20.6.3 Key Strategies
20.6.4 Key Strengths
20.6.5 Key Opportunities
20.7 AOP Orphan Pharmaceuticals
20.7.1 Business Overview
20.7.2 Major Product Offerings
20.7.3 Key Strategies
20.7.4 Key Strengths
20.7.5 Key Opportunities

21 Other Vendors
21.1 Pfizer
21.1.1 Business Overview
21.1.2 Product Offerings
21.2 Sunny Pharmaceutical
21.2.1 Business Overview
21.2.2 Product Offerings
21.3 MEDICE
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 AZAD Pharma
21.4.1 Business Overview
21.4.2 Product Offerings
21.5 Cirondrugs
21.5.1 Business Overview
21.5.2 Product Offerings
21.6 Salveo Lifecare
21.6.1 Business Overview
21.6.2 Product Offerings

22 Report Summary
22.1 Key Takeaways
22.2 Strategic Recommendations
22.3 Quantitative Summary
22.3.1 By ROA
22.3.2 By Application
22.3.3 By Geography

23 Appendix
23.1 Abbreviations

List of Exhibits
Exhibit 1 Segmentation of Global IV & Oral Iron Drugs Market
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Impact of Expanding Population Pool with Iron Deficiency
Exhibit 4 Prevalence Rate of Anemia in Infants and Young Children (0−5 years) 2015
Exhibit 5 Global Prevalence of Anemia in Different Population Groups
Exhibit 6 Percentage of Patients Affected with IDA in Various Diseases
Exhibit 7 Impact of High Demand for Non-dextran IV Iron Therapeutics
Exhibit 8 Vifor Pharma Group’s Ferinject Revenue 2016−2018 ($ million)
Exhibit 9 Daiichi Sankyo Company Ferinject Revenue 2015−2018 ($ million)
Exhibit 10 AMAG Pharmaceuticals’ Feraheme 2016−2018 ($ million)
Exhibit 11 Impact of Rising Demand Among Dialysis and Non-dialysis Patients
Exhibit 12 Anemia Prevalence Rate Comparison Between General Population and CKD Patients
Exhibit 13 Revenue of Branded IV Iron Drugs Indicated for IDA in CKD Patients 2018 ($ million)
Exhibit 14 Impact of Adverse Events Associated with Oral & IV Iron Drugs
Exhibit 15 Impact of Presence of Alternative Options for Treating ID and IDA
Exhibit 16 Popular Alternative Options for Treating ID/IDA
Exhibit 17 Impact of Availability of Low-cost Generic Iron Drugs
Exhibit 18 Percentage Share of Prescription Iron Drugs by Region 2018
Exhibit 19 Impact of Investigational Iron Drugs and Expected Approvals in Newer Markets
Exhibit 20 Impact of Increase in Strategic Collaborations and Licensing Opportunities
Exhibit 21 Impact of Availability of Branded Iron Therapeutics and Expanded Indication Approvals
Exhibit 22 Global IV & Oral Iron Drugs Market by Application 2018 & 2024 (%)
Exhibit 23 Global IV & Oral Iron Drugs Market by ROA 2018 & 2024 (%)
Exhibit 24 Global IV & Oral Iron Drugs Market 2018−2024 ($ million)
Exhibit 25 Global IV & Oral Iron Drugs Market by Region: Market Snapshot
Exhibit 26 Global IV & Oral Iron Drugs Market by Geography: Incremental Growth
Exhibit 27 Global IV & Oral Iron Drugs Market by ROA: Incremental Growth
Exhibit 28 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
Exhibit 29 Five Forces Analysis 2018
Exhibit 30 Incremental Growth by ROA 2018−2024
Exhibit 31 Global IV & Oral Iron Drugs Market by ROA 2018−2024 (%)
Exhibit 32 Global IV & Oral Iron Drugs Market by ROA Type: Absolute Growth
Exhibit 33 Global IV & Oral Iron Drugs Market 2018 & 2024 (%)
Exhibit 34 Global IV & Oral Iron Drugs Market 2018−2024 ($ million)
Exhibit 35 Global IV & Oral Iron Drugs Market 2018−2024 (%)
Exhibit 36 Maltofer Revenue 2017 & 2018 ($ million)
Exhibit 37 Feraccru Revenue 2016 & 2018 ($ million)
Exhibit 38 Global Oral Iron Drugs Market 2018−2024 ($ million)
Exhibit 39 Vifor Pharma Group’s Revenue for Ferinject/Injectafer 2016−2018 ($ million)
Exhibit 40 Daiichi Sankyo Group’s Revenue for Injectafer 2015−2018 ($ million)
Exhibit 41 Venofer Revenue 2017 & 2018 ($ million)
Exhibit 42 AMAG Pharmaceuticals’ Feraheme 2016−2018 revenue ($ million)
Exhibit 43 Global IV Iron Drugs Market 2018−2024 ($ million)
Exhibit 44 Incremental Growth by Application 2018−2024
Exhibit 45 Global IV & Oral Iron Drugs Market by Application Type
Exhibit 46 Global IV & Oral Iron Drugs Market by Application Type 2018 & 2024 (%)
Exhibit 47 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
Exhibit 48 Global IV & Oral Iron Drugs Market by Application Type 2018−2024 ($ million)
Exhibit 49 Global IV & Oral Iron Drugs Market by Application Type 2018−2024 (%)
Exhibit 50 Global IV & Oral Iron Drugs Market by Application: Absolute Growth
Exhibit 51 Global IV & Oral Nephrology Iron Drugs Market 2018−2024 ($ million)
Exhibit 52 Global IV & Oral OBGYN Iron Drugs Market 2018−2024 ($ million)
Exhibit 53 Global IV & Oral Surgeries Iron Drugs Market 2018−2024 ($ million)
Exhibit 54 Global IV & Oral Gastroenterology Iron Drugs Market 2018−2024 ($ million)
Exhibit 55 Global IV & Oral Oncology Iron Drugs Market 2018−2024 ($ million)
Exhibit 56 Global IV & Oral HF Iron Drugs Market 2018−2024 ($ million)
Exhibit 57 Incremental Growth by Geography 2018−2024
Exhibit 58 Global IV & Oral Iron Drugs Market by Region
Exhibit 59 Global IV & Oral Iron Drugs Market by Geography: 2018 Market Shares (%)
Exhibit 60 Global IV & Oral Iron Drugs Market by Region: Incremental Growth (2018−2024)
Exhibit 61 Global IV & Oral Iron Drugs Market by Region 2018 & 2024 (%)
Exhibit 62 Global IV & Oral Iron Drugs Market by Region 2018−2024 ($ million)
Exhibit 63 Global IV & Oral Iron Drugs Market by Region 2018−2024 (%)
Exhibit 64 IV & Oral Iron Drugs Market in North America 2018 (%)
Exhibit 65 Prevalence of CKD in US 2001−2016 (%)
Exhibit 66 IV & Oral Iron Drugs Market in North America 2018–2024 ($ million)
Exhibit 67 Incremental Growth in North America 2018−2024
Exhibit 68 IV & Oral Iron Drugs Market in US 2018−2024 ($ million)
Exhibit 69 IV & Oral Iron Drugs Market in Canada 2018−2024 ($ million)
Exhibit 70 IV & Oral Iron Drugs Market in Europe 2018 (%)
Exhibit 71 IV & Oral Iron Drugs Market in Europe 2018–2024 ($ million)
Exhibit 72 Incremental Growth in Europe 2018−2024
Exhibit 73 IV & Oral Iron Drugs Market in Germany 2018–2024 ($ million)
Exhibit 74 IV & Oral Iron Drugs Market in UK 2018–2024 ($ million)
Exhibit 75 IV & Oral Iron Drugs Market in France 2018–2024 ($ million)
Exhibit 76 IV & Oral Iron Drugs Market in Spain 2018–2024 ($ million)
Exhibit 77 IV & Oral Iron Drugs Market in Italy 2018–2024 ($ million)
Exhibit 78 IV & Oral Iron Drugs Market in APAC 2018 (%)
Exhibit 79 IV & Oral Iron Drugs Market in APAC 2018–2024 ($ million)
Exhibit 80 Incremental Growth in APAC 2018–2024
Exhibit 81 IV & Oral Iron Drugs Market in Japan 2018–2024 ($ million)
Exhibit 82 IV & Oral Iron Drugs Market in China 2018–2024 ($ million)
Exhibit 83 IV & Oral Iron Drugs Market in Australia 2018−2024 ($ million)
Exhibit 84 IV & Oral Iron Drugs Market in South Korea 2018−2024 ($ million)
Exhibit 85 IV & Oral Iron Drugs Market in Latin America by Country 2018 (%)
Exhibit 86 IV & Oral Iron Drugs Market in Latin America 2018−2024 ($ million)
Exhibit 87 Incremental Growth in Latin America 2018–2024
Exhibit 88 IV & Oral Iron Drugs Market in Brazil 2018–2024 ($ million)
Exhibit 89 IV & Oral Iron Drugs Market in Mexico 2018–2024 ($ million)
Exhibit 90 IV& Oral Iron Drugs Market in MEA 2018−2024 ($ million)
Exhibit 91 Incremental Growth in MEA 2018–2024
Exhibit 92 IV & Oral Iron Drugs Market in Turkey 2018–2024 ($ million)
Exhibit 93 IV & Oral Iron Drugs Market in Saudi Arabia 2018–2024 ($ million)
Exhibit 94 Strategic Recommendations for Market Participants
Exhibit 95 Vifor Pharma Group: Ferinject/Injectafer Revenue Breakdown by Region 2018 (%)
Exhibit 96 Vifor Pharma Group: Ferinject/Injectafer Revenue 2016−2018 ($ million)
Exhibit 97 Venofer Net Sales 2017 & 2018 ($ million)
Exhibit 98 Maltofer Net Sales 2017 & 2018 ($ million)
Exhibit 99 Daiichi Sankyo Company Revenue Breakdown by Region FY2017 (%)
Exhibit 100 American Regent Revenue Breakdown by Business Units FY2016 & FY2017 (%)
Exhibit 101 Daiichi Sankyo Company’s Injectafer Revenue 2015-2017 ($ million)
Exhibit 102 Exhibit 57 Daiichi Sankyo Company’s Venofer Revenue 2016 & 2017 ($ million)
Exhibit 103 AMAG Pharmaceuticals Revenue 2016−2018 ($ million)
Exhibit 104 AMAG Pharmaceuticals Revenue by Drugs 2018 (%)
Exhibit 105 Feraheme Revenue 2016–2018 ($ million)
Exhibit 106 Akebia Therapeutics Revenue Breakdown FY2018 (%)
Exhibit 107 Shield Therapeutics’ Revenue 2016–2018 ($ million)
Exhibit 108 Allergan Revenue Breakdown by Business Segments FY2018 (%)
Exhibit 109 Sanofi Revenue Breakdown by Healthcare Area 2018 (%)
Exhibit 110 Sanofi Revenue Breakdown by Geographic Area 2018 (%)

List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2018
Table 3 Standard Requirement of Iron in Different Patient Groups
Table 4 Oral Iron Therapy: Advantages and Disadvantages
Table 5 IV Iron: Advantages and Disadvantages
Table 6 Characteristics of Oral and IV Iron Drugs
Table 7 Popular Prescription Drugs Used for Treating IDA in CKD Patients
Table 8 Most Popular Food Sources with High Iron Levels
Table 9 Investigational Iron Therapeutics Under Development
Table 10 Tentative Approval/Launch of Popular Iron Drugs in Various Countries/Regions
Table 11 Major Strategic Collaborations and Licensing Partnerships
Table 12 Major Iron Drugs Approved in Various Countries/Regions
Table 13 Expanded Indication Approvals for Already Commercialized IV & oral Iron Drugs
Table 14 Popular IV and Oral Iron Drugs Available
Table 15 Characteristics of Oran and IV Iron Drugs
Table 16 Most Common Oral Iron Drug Preparations
Table 17 Popular Branded Oral Iron Drugs Commercially Available
Table 18 Popular Branded IV Iron Drugs
Table 19 Popular Iron Drugs Available for Treating ID in CKD Patients
Table 20 Iron Supplementation Dosage Among Children
Table 21 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients
Table 22 Recommendations on Iron Therapy for Anemia and ID in Cancer Patients
Table 23 Iron-Containing Proteins Altered in Heart Failure Patients
Table 24 Current Guideline Recommendations for IV Iron in Heart Failure Patients
Table 25 Popular Branded Iron Drugs Available in North America
Table 26 Popular Branded Iron Drugs Available in the US
Table 27 Popular Branded Iron Drugs Available in Canada
Table 28 Prevalence of ID and IDA in Major Europe Countries (EU15)
Table 29 Popular Branded Iron Drugs Available in Europe
Table 30 Competitive Structure Analysis of Global IV & Oral Iron Drugs Market 2018
Table 31 Global IV & Oral Iron Drugs Market: Vendors Ranking 2018
Table 32 Ranking of Vendors Offering Branded IV and Oral Iron Drugs
Table 33 Daiichi Sankyo Group R&D Pipeline Highlights (As of July 2018)
Table 34 Daiichi Sankyo Group’s Innovative Pharmaceuticals Business Key Products
Table 35 Daiichi Sankyo Company: Product Offerings
Table 36 AMAG Pharmaceuticals Marketed and Investigational Products Status
Table 37 AMAG Pharmaceuticals: Product Offerings
Table 38 Akebia Therapeutics: Product Offerings
Table 39 Shield Therapeutics: Pipeline Highlights
Table 40 Shield Therapeutics: Product Offerings
Table 41 Pharmacosmos: Product Offerings
Table 42 Allergan’s Recent Acquisitions
Table 43 Allergan: Product Offerings
Table 44 Sanofi: Product Offerings
Table 45 AOP Orphan Pharmaceuticals: Product Offerings
Table 46 Pfizer: Key Product Offerings
Table 47 Sunny Pharmaceutical: Key Product Offerings
Table 48 MEDICE: Key Product Offerings
Table 49 AZAD Pharma: Key Product Offerings
Table 50 Cirondrugs: Key Product Offerings
Table 51 Salveo Lifecare: Key Product Offerings
Table 52 Global IV & Oral Iron Drugs Market by Products ($ million)
Table 53 Global IV & Oral Iron Drugs Market by Products (%)
Table 54 Global IV & Oral Iron Drugs Market by Application ($ million)
Table 55 Global IV & Oral Iron Drugs Market by Applications (%)
Table 56 Global IV & Oral Iron Drugs Market by Geography ($ million)
Table 57 Global IV & Oral Iron Drugs Market by Geography (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Daiichi Sankyo Company
  • Vifor Pharma
  • Akebia Therapeutics
  • Allergan
  • AMAG Pharmaceuticals
  • AOP Orphan Pharmaceuticals
  • Pharmacosmos
  • Sanofi
  • Shield Therapeutics
  • AZAD PharmaCirondrugs
  • MEDICE
  • Pfizer
  • Salveo Lifecare
  • Sunny Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll